[1]郑高梅.沙库巴曲缬沙坦钠治疗老年射血分数降低的心力衰竭疗效观察[J].新乡医学院学报,2022,39(8):767-771.[doi:10.7683/xxyxyxb.2022.08.013]
　ZHENG Gaomei.Curative effect of sacubitril and valsartan sodium in the treatment of elderly patients with heart failure with reduced ejection fraction[J].Journal of Xinxiang Medical University,2022,39(8):767-771.[doi:10.7683/xxyxyxb.2022.08.013]
点击复制

沙库巴曲缬沙坦钠治疗老年射血分数降低的心力衰竭疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年8
页码:
767-771
栏目:
临床研究
出版日期:
2022-08-05

文章信息/Info

Title:
Curative effect of sacubitril and valsartan sodium in the treatment of elderly patients with heart failure with reduced ejection fraction
作者:
郑高梅
（阜阳市人民医院心血管内科，安徽　阜阳　236000）
Author(s):
ZHENG Gaomei
（Department of Internal Medicine-Cardiovascular，Fuyang People′s Hospital，Fuyang 236000，Anhui Province，China）
关键词:
慢性心力衰竭; 沙库巴曲缬沙坦钠; 血管紧张素转化酶抑制剂; 血清氨基末端脑钠肽; 不良反应
Keywords:
chronic heart failure; sacubitril and valsartan sodium; angiotensin converting enzyme inhibitor; serum N-terminal brain natriuretic peptide; adverse reaction
分类号:
R541.6
DOI:
10.7683/xxyxyxb.2022.08.013
文献标志码:
A
摘要:
目的　探讨沙库巴曲缬沙坦钠治疗射血分数降低的心力衰竭（HFrEF）老年患者的临床疗效。方法　选择2019年1月至2020年7月阜阳市人民医院收治的86例老年HFrEF患者为研究对象，根据治疗方法将患者分为对照组和观察组，每组43例。对照组患者给予盐酸贝那普利片10 mg，口服，每日1次，每2周对患者的药物耐受性进行评价，缓慢调整药物用量至每次20 mg，每日1次，连续治疗12周。观察组患者给予沙库巴曲缬沙坦钠片口服，每次50 mg，每日2次，每2周对患者的药物耐受性进行评价，缓慢调整药物用量至每次100 mg，每日2次，连续治疗12周。治疗后 7 d，对2组患者的临床疗效进行评估，并计算总有效率。分别于治疗前和治疗后7 d，应用彩色多普勒超声检测2组患者心功能，包括左心室射血分数（LVEF）、左心室舒张末期内径（LVEDD）和每搏输出量（SV）；采用6 min 步行实验评估2组患者的运动耐力，记录6 min步行距离（6MWD）；采用全自动化学发光免疫分析法检测2组患者血清氨基末端脑利钠肽前体(NT-proBNP)、 C反应蛋白（CRP）水平；采用酶联免疫吸附试验测定2组患者血清同型半胱氨酸（Hcy）水平。记录2组患者随访90 d内心力衰竭恶化、高钾血症、肾功能损伤的发生情况，并计算不良反应发生率。结果　对照组患者显效16例，有效18例，无效9例，总有效率为 79.07%（34/43）；观察组患者显效24例，有效17例，无效2例，总有效率为 95.35%（41/43）；观察组患者治疗总有效率显著高于对照组（χ2=5.108，P<0.05）。治疗前，2组患者的LVEF、LVEDD、SV、6MWD比较差异无统计学意义（P>0.05）；2组患者治疗后7 d的LVEF、SV、6MWD显著高于治疗前，LVEDD显著低于治疗前（P<0.05）；治疗后7 d，观察组患者的LVEF、SV、6MWD显著高于对照组，LVEDD显著低于对照组（P<0.05）。 治疗前，2组患者的NT-proBNP、Hcy、CRP水平比较差异无统计学意义（P>0.05）；2组患者治疗后7 d的NT-proBNP、Hcy、CRP水平均显著低于治疗前（P<0.05）；治疗后7 d，观察组患者的NT-proBNP、Hcy、CRP水平显著低于对照组（P<0.05）。 治疗后90 d内，对照组和观察组患者不良反应发生率分别为11.63%（5/43）和 2.32%（1/43）；2组患者的不良反应发生率比较差异无统计学意义（χ2=2.867，P>0.05）。结论　沙库巴曲缬沙坦钠对老年HFrEF患者具有良好的临床疗效，可提升患者的心功能，减轻炎症反应，且不良反应发生率低。
Abstract:
Objective　To investigate the clinical efficacy of sacubitril and valsartan sodium in the treatment of elderly patients with heart failure with reduced ejection fraction （HFrEF）.Methods　A total of 86 elderly patients with HFrEF admitted to the Fuyang People′s Hospital from January 2019 to July 2020 were selected as the research objects.According to the treatment methods，the patients were divided into the control group and the observation group，with 43 cases in each group.The patients in the control group were given benazepril hydrochloride tablets orally，10 mg once a day，and the drug tolerance of the patients was evaluated every two weeks，and the drug dosage was slowly adjusted to 20 mg once a day，continuously twelve weeks of treatment.The patients in the observation group were given sacubitril and valsartan sodium tablets orally，50 mg twice a day，and the drug tolerance of the patients was evaluated every two weeks，and the drug dosage was slowly adjusted to 100 mg twice a day，continuously twelve weeks of treatment.At 7 days after treatment，the clinical efficacy of patients in the two groups was evaluated，and the total effective rate was calculated.Before treatment and 7 days after treatment，cardiac function was detected by color Doppler ultrasound，including left ventricular ejection fractions (LVEF)，left ventricular end-diastolic diameter (LVEDD) and stroke volume (SV)；the exercise tolerance of patients in the two groups was evaluated by 6-minute walking test，and 6-minute walking distance (6MWD) was recorded；the levels of N-terminal probrain natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) in serum of patients in the two groups were detected by automatic chemiluminescence immunoassay；the level of homocysteine (Hcy) in serum of patients in the two groups was determined by enzyme-linked immunosorbent assay.The incidences of heart failure worsening，hyperkalemia and renal function damage within 90 days of follow-up of patients in the two groups were recorded，and the incidence of adverse reactions was calculated.Results　In the control group，16 cases were markedly effective，18 cases were effective，and 9 cases were ineffective，with a total effective rate of 79.07% (34/43)；in the observation group，24 cases were markedly effective，17 cases were effective，and 2 cases were ineffective，with a total effective rate of 95.35%（41/43）；the total effective rate of patients in the observation group was significantly higher than that in the control group (χ2=5.108，P<0.05).Before treatment，there was no significant difference in LVEF，LVEDD，SV and 6MWD of patients between the two groups (P>0.05)；the LVEF，SV and 6MWD of patients in the two groups at 7 days after treatment were significantly higher than those before treatment，and the LVEDD was significantly lower than that before treatment (P<0.05)；at 7 days after treatment，the LVEF，SV and 6MWD of patients in the observation group were significantly higher than those in the control group，and the LVEDD was significantly lower than that in the control group (P<0.05).Before treatment，there was no significant difference in the levels of NT-proBNP，Hcy and CRP in serum of patients between the two groups (P>0.05)；the levels of NT-proBNP，Hcy and CRP in serum of patients in the two groups at 7 days after treatment were significantly lower than those before treatment (P<0.05)；at 7 days after treatment，the levels of NT-proBNP，Hcy and CRP in serum of patients in the observation group were significantly lower than those in the control group (P<0.05).Within 90 days after treatment，the incidence of adverse reactions in the control group and observation group were 11.63% (5/43) and 2.32% (1/43)，respectively；there was no significant difference in the incidence of adverse reactions between the two groups (χ2=2.867，P>0.05).Conclusion　　Sacubatril and valsartan sodium has good clinical efficacy in elderly patients with HFrEF，which can improve patients′ cardiac function，reduce inflammatory response，and has a low incidence of adverse reactions.

参考文献/References:

［1］　马柳一，尹玉洁，李红蓉，等.慢性心力衰竭患者交感神经激活的中枢机制及治疗进展［J］.中国老年学杂志，2016，36(12)：3068-3071.
MA L Y，YIN Y J，LI H R，et al.The central mechanism and treatment progress of sympathetic nerve activation in patients with chronic heart failure［J］.Chin J Gerontol，2016，36(12)：3068-3071.
［2］　杨贝贝，郑战战，吴圣佳，等.慢性稳定性心力衰竭患者症状群分类的研究［J］.中国护理管理，2018，18(2)：185-191.
YANG B B，ZHENG Z Z，WU S J，et al.Identification of symptom clusters in patients with chronic stable heart failure［J］.Chin Nurs Mgmt，2018，18(2)：185-191.
［3］　孙桂锋，刘宇，李艳，等.基层医院慢性心力衰竭治疗现状调查［J］.中国全科医学，2018，21(11)：1280-1284.
SUN G F，LIU Y，LI Y，et al.Treatment status of heart failure in grassroots medical institutions in China′s Liaocheng［J］.Chin Gen Pract，2018，21(11)：1280-1284.
［4］　倪晶宇，李澜，李敏，等.慢性心力衰竭与能量代谢重构关系的研究进展［J］.中国临床药理学杂志，2017，33(5)：474-477.
NI J Y，LI L，LI M，et al.Research progress on the relationship between chronic heart failure and energy metabolism remodeling［J］.Chin J Clin Pharmacol，2017，33(5)：474-477.
［5］　MARQUES DA SILVA P，AGUIAR C.Sacubitril/valsartan：an important piece in the therapeutic puzzle of heart failure［J］.Rev Port Cardiol，2017，36(9)：655-668.
［6］　马丽娜.衰弱与老年人心血管病的关系［J］.中华高血压杂志，2017，25(4)：384-387.
MA L N.The relationship between frailty and cardiovascular disease in the elderly［J］.Chin J Hypertens，2017，25(4)：384-387.
［7］　夏健宁，彭哲.血管紧张素转化酶抑制剂类药物治疗老年慢性心力衰竭的研究进展［J］.中国预防医学杂志，2017，18(4)：290-293.
XIA J N，PENG Z.Research progress of angiotensin-converting enzyme inhibitors in the treatment of elderly chronic heart failure［J］.Chin Prev Med，2017，18(4)：290-293.
［8］　YANCY C W，JESSUP M，BOZKURT B，et al.2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure：a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America［J］.Circulation，2017，136(6)：e137-e161.
［9］　中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南（2014版）［J］.中华心血管病杂志，2014，42(2)：98-122.
CARDIOVASCULAR BRANCH OF CHINESE MEDICAL ASSOCIATION，EDITORIAL BOARD OF CHINESE JOURNAL OF CARDIOVASCULAR DISEASES.Guidelines for diagnosis and treatment of heart failure in China (2014 edition)［J］.Chin J Cardiol，2014，42(2)：98-122.
［10］　毛承誉，朱华芳，张田田，等.上海市社区中老年人群心力衰竭患病率流行病学调查研究［J］.中国预防医学杂志，2019，20(2)：124-127.
MAO C Y，ZHU H F，ZHANG T T，et al.The epidemiological features of chronic heart failure among the middle-aged and the elderly in communities in Shanghai［J］.Chin Prev Med，2019，20(2)：124-127.
［11］　张晓雷，萨支红.慢性心力衰竭患者及家庭照顾者疾病管理和生活质量现况［J］.中国老年学杂志，2017，37(4)：981-983.
ZHANG X L，SA Z H.Status of disease management and quality of life in patients with chronic heart failure and their family caregivers［J］.Chin J Gerontol，2017，37(4)：981-983.
［12］　王洁，蒋捷，褚松筠，等.慢性缺血性心力衰竭患者指南指导下的用药现状［J］.中国临床药理学杂志，2019，35(24)：3183-3186.
WANG J，JIANG J，CHU S Y，et al.Current status of medication under the guidance of guidelines for patients with chronic ischemic heart failure［J］.Chin J Clin Pharmacol，2019，35(24)：3183-3186.
［13］　许顶立，马壮.2018英国国家卫生与临床优化研究所成年人慢性心力衰竭诊断与管理指南更新解读［J］.中国全科医学，2019，22(17)：2015-2019.
XU D L，MA Z.Interpretation of the updates in 2018 NICE guideline for the diagnosis and management of chronic heart failure in adults［J］.Chin Gen Pract，2019，22(17)：2015-2019.
［14］　TOMASONI D，ADAMO M，LOMBARDI C M，et al.Highlights in heart failure［J］.ESC Heart Fail，2019，6(6)：1105-1127.
［15］　VARDENY O，CLAGGETT B，KACHADOURIAN J，et al.Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril：the PARADIGM-HF trial［J］.Eur J Heart Fail，2019，21(3)：337-341.
［16］　周丽华，杨威，吉中蛟.老年慢性心力衰竭患者血清MR-ProADM、miRNA-21水平变化与预后的关系研究［J］.中国免疫学杂志，2019，35(23)：2904-2907，2910.
ZHOU L H，YANG W，JI Z J.Relationship between serum MR-ProADM，miRNA-21 levels and prognosis in elderly patients with chronic heart failure［J］.Chin J Immunol，2019，35(23)：2904-2907，2910.
［17］　SOLOMON S D，JHUND P S，CLAGGETT B L，et al.Effect of dapagliflozin in patients with HFrEF treated with sacubitril/valsartan：the DAPA-HF trial［J］.JACC Heart Fail，2020，8(10)：811-818.
［18］　HAMANO G，YAMAMOTO K，TAKAMI Y，et al.Effects of low-dose sacubitril/valsartan on different stages of cardiac hypertrophy in salt-loaded hypertensive rats［J］.J Cardiovasc Pharmacol，2019，73(5)：282-289.
［19］　TER MAATEN J M.Unraveling the effect of sacubitril/valsartan on loop diuretic dosing［J］.Eur J Heart Fail，2019，21(3)：342-344.
［20］　贾红丹，丛洪良，赵云凤，等.沙库巴曲缬沙坦治疗慢性心力衰竭患者的疗效观察［J］.天津医药，2019，47(10)：1076-1080.
JIA H D，CONG H L，ZHAO Y F，et al.The efficiency of sacubitril/valsartan therapy in patients with chronic heart failure［J］.Tianjin Med J，2019，47(10)：1076-1080.
［21］　王勉，胡静静，蔡兆斌.沙库巴曲缬沙坦在心血管疾病中的多效性研究进展［J］.中国现代应用药学，2019，36(17)：2236-2239.
WANG M，HU J J，CAI Y B.Advances research of sacubitril-valsartan′s pleiotropic effects on cardiovascular diseases［J］.Chin J Mod Appl Pharm，2019，36(17)：2236-2239.
［22］　PONTREMOLI R，BORGHI C，PERRONE FILARDI P.Renal protection in chronic heart failure：focus on sacubitril/valsartan［J］.Eur Heart J Cardiovasc Pharmacother，2021，7(5)：445-452.

相似文献/References:

[1]刘阳责,李维国,凌 云· 王明焱,等.倍他乐克对慢性心力衰竭的治疗价值[J].新乡医学院学报,2000,17(02):095.
[2]韩 曼,马 莉,于远望.2种慢性心力衰竭大鼠模型的建立[J].新乡医学院学报,2015,32(11):992.
[3]董　征,周雯雯.慢性心力衰竭患者心脏同步化治疗效果与肺动脉收缩压的关系[J].新乡医学院学报,2016,33(10):887.[doi:10.7683/xxyxyxb.2016.10.013]
　DONG Zheng,ZHOU Wen-wen.Relationship between the effect of cardiac resynchronization therapy and pulmonary artery systolic pressure in patients with chronic heart failure[J].Journal of Xinxiang Medical University,2016,33(8):887.[doi:10.7683/xxyxyxb.2016.10.013]
[4]张全英,孙俊俊,张朝辉,等.情绪体验在慢性心力衰竭患者主要照顾者精力与照顾者负担间的中介作用[J].新乡医学院学报,2021,38(5):422.[doi:10.7683/xxyxyxb.2021.05.005]
　ZHANG Quanying,SUN Junjun,ZHANG Zhaohui,et al.Mediating role of emotion between energy and burden in major caregivers of chronic heart failure patients[J].Journal of Xinxiang Medical University,2021,38(8):422.[doi:10.7683/xxyxyxb.2021.05.005]
[5]杨秀丽,孙海燕,潘瑞阳,等.辛伐他汀对慢性心力衰竭兔心肌细胞凋亡的影响[J].新乡医学院学报,2019,36(10):907.[doi:10.7683/xxyxyxb.2019.10.002]
　YANG Xiu-li,SUN Hai-yan,PAN Rui-yang,et al.Effects of simvastatin on cardiomyocyte apoptosis in rabbits with chronic heart failure[J].Journal of Xinxiang Medical University,2019,36(8):907.[doi:10.7683/xxyxyxb.2019.10.002]
[6]韩亚军,张荣怀,王晓明.左西孟旦注射液和托拉塞米注射液联合治疗老年慢性心力衰竭疗效观察[J].新乡医学院学报,2021,38(1):057.[doi:10.7683/xxyxyxb.2021.01.012]
　HAN Yajun,ZHANG Ronghuai,WANG Xiaoming.Curative effect of levosimendan injection combined with torasemide injection in the treatment of elderly patients with chronic heart failure[J].Journal of Xinxiang Medical University,2021,38(8):057.[doi:10.7683/xxyxyxb.2021.01.012]
[7]周翠翠,吕风华,王现伟.血清同型半胱氨酸和胱抑素C对慢性心力衰竭患者早期肾损伤的诊断价值[J].新乡医学院学报,2021,38(11):1025.[doi:10.7683/xxyxyxb.2021.11.005]
　ZHOU Cuicui,LYU Fenghua,WANG Xianwei.Clinical value of serum homocysteine and cystatin C in the diagnosis of early renal injury in patients with chronic heart failure[J].Journal of Xinxiang Medical University,2021,38(8):1025.[doi:10.7683/xxyxyxb.2021.11.005]
[8]赵　云,王玉华,赵国安,等.辛伐他汀对慢性心力衰竭兔心肌沉默信息调节因子2相关酶2/核因子-κB信号通路的影响[J].新乡医学院学报,2017,34(2):094.[doi:10.7683/xxyxyxb.2017.02.004]
　ZHAO Yun,WANG Yu-hua,ZHAO Guo-an,et al.Effects of simvastatin on myocardial silent mating type information regulation 2 homolog-2/nuclear factor-κB signaling pathway in rabbits with chronic heart failure[J].Journal of Xinxiang Medical University,2017,34(8):094.[doi:10.7683/xxyxyxb.2017.02.004]
[9]彭　敏,闫　超.瑞舒伐他汀钙对老年慢性心力衰竭患者氧化-抗氧化系统及血管内皮细胞功能的影响[J].新乡医学院学报,2017,34(8):751.[doi:10.7683/xxyxyxb.2017.08.024]
　PENG Min,YAN Chao.Effects of rosuvastatin calcium on oxidation-antioxidation system and vascular endothelial cell function in elderly patients with chronic heart failure[J].Journal of Xinxiang Medical University,2017,34(8):751.[doi:10.7683/xxyxyxb.2017.08.024]
[10]潘瑞洋,孙家珍,赵奕霖,等.辛伐他汀对慢性心力衰竭兔人第10号染色体缺失的磷酸酶及张力蛋白同源基因和β-catenin表达的影响[J].新乡医学院学报,2017,34(12):1048.[doi:10.7683/xxyxyxb.2017.12.002]
　PAN Rui-yang,SUN Jia-zhen,ZHAO Yi-lin,et al.Effect of simvastatin on phosphatase and tensin homologue deleted on chromosome ten and β-catenin of rabbits with chronic heart failure[J].Journal of Xinxiang Medical University,2017,34(8):1048.[doi:10.7683/xxyxyxb.2017.12.002]

更新日期/Last Update: 2022-08-05